Heron Therapeutics, Inc. (HRTX)
- Sector
- Biotechnology
- Last price
- $0.31
- As of
Kresmion compiles this page from HRTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
HERON THERAPEUTICS, INC. /DE/ (HRTX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
See the full HRTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for HRTX on one page. Preview it with sample data, then open it live with a free account.
Preview the HRTX dossierActive events for HRTX
- high13F: large reduction
D. E. Shaw & Co., Inc. cut 95% of HRTX (2026Q2)
- high13F: large reduction
TWO SIGMA INVESTMENTS, LP cut 68% of HRTX (2026Q1)
- lowEarnings below estimates
Q3-2025: EPS $-0.04 vs $-0.0153 estimate, -0.02 on a near-zero consensus
- lowEarnings below estimates
Q2-2025: EPS $-0.02 vs $-0.0102 estimate, -0.01 on a near-zero consensus
- lowEarnings below estimates
Q1-2026: EPS $-0.04 vs $-0.0153 estimate, -0.02 on a near-zero consensus
FREE, NO ACCOUNT
Every event on HRTX, as it fires
New filings, 13F moves and cross asset events on HRTX land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in HRTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 427746102 · 2026Q2 | $1.7M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 427746102 · 2026Q2 | $643K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 427746102 · 2026Q2 | $114K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 427746102 · 2026Q2 | $51K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, HRTX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
HRTX against its peers
HRTX's operating margin of -1.6% ranks in the 85th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-04-30 and 2025-12-31.
| Metric | HRTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 155M USD | 11.9M USD | 96 | 12 |
| Gross margin | 73.3% | n/a | n/a | 4 |
| Operating margin | -1.6% | -111.0% | 85 | 9 |
| Net margin | -13.0% | -101.7% | 77 | 10 |
| Return on equity | -140.9% | -108.6% | 36 | 17 |
Peers (24): CRBU, OSTX, XLO, BOLD, GOSS, VRCA, INKT, XBIT, RNXT, ELOX, ONCY, FBIO, AURX, ELTX, HYFT, HOWL, TENX, RNTX, GANX, SPRO, SGMOQ, LONA, CGTX, CING. Left out: APLM (period gap). Fiscal periods ending between 2025-04-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (HRTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow HRTX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to HRTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.